680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials.

MLA

Zirwas, Matthew J., et al. “680 - Efficacy of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis by Age of Onset: Analysis of Two Phase 3 Clinical Trials.” British Journal of Dermatology, vol. 191, Aug. 2024, pp. 1–3. EBSCOhost, https://doi.org/10.1093/bjd/ljae266.054.

APA

Zirwas, M. J., Boguniewicz, M., Rosmarin, D., Fuxench, Z. C., Warren, R. B., Torres, T., Bruin-Weller, M. de, Dawson, Z., Atwater, A. R., Elmaraghy, H., Pierce, E., Bardolet, L., Zhong, J., & Armstrong, A. W. (2024). 680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials. British Journal of Dermatology, 191, 1–3. https://doi.org/10.1093/bjd/ljae266.054

Chicago

Zirwas, Matthew J, Mark Boguniewicz, David Rosmarin, Zelma Chiesa Fuxench, Richard B Warren, Tiago Torres, Marjolein de Bruin-Weller, et al. 2024. “680 - Efficacy of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis by Age of Onset: Analysis of Two Phase 3 Clinical Trials.” British Journal of Dermatology 191 (August): 1–3. doi:10.1093/bjd/ljae266.054.